2.
Ben-Avraham, S, Harman-Boehm, I, Schwarzfuchs, D
et al. (2009) Dietary strategies for patients with type 2 diabetes in the era of multi-approaches; review and results from the dietary intervention randomized controlled trial (DIRECT). Diabetes Res Clin Pract
86, S41–S48.
3.
Drucker, DJ (2006) The biology of incretin hormones. Cell Metab
3, 153–165.
4.
Drucker, DJ (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes. Diabetes Care
30, 1335–1343.
5.
Gupta, V & Kalra, S (2011) Choosing a gliptin. Indian J Endo Metab
15, 298–308.
6.
Krushner, P & Gorrell, M (2010) DPP-4 inhibitors in type 2 diabetes: importance of selective enzyme inhibition and implications for clinical use. J Fam Pract
59, 2.
7.
American Diabetes Association (2009) Standards of medical care in diabetes—2009. Diabetes Care
32, S13–S61.
8.
FitzGerald, RJ & Meisel, H (2003) Milk protein hydrolysates and bioactive peptides. In Advanced Dairy Chemistry 1: Proteins, 3rd ed., pp. 675–698 [Fox, PF & Mc Sweeney, PLH, editors]. New York: Kluwer Academic/Plenum Publishers.
9.
Murray, BA & FitzGerald, RJ (2007) Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production. Curr Pharm Des
13, 773–791.
10.
Frid, AH, Nilsson, M, Holst, JJ
et al. (2005) Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr
82, 69–75.
11.
Manders, RJF, Wagenmakers, AJM, Koopman, R
et al. (2005) Co-ingestion of a protein hydrolysate and amino acid mixture with carbohydrate improves plasma glucose disposal in patients with type 2 diabetes. Am J Clin Nutr
82, 76–83.
12.
Lacroix, IME & Li-Chan, ECY (2012) Dipeptidyl peptidase-IV inhibitory activity of dairy protein hydrolysates. Int Dairy J
25, 97–102.
13.
Nongonierma, AB & FitzGerald, RJ (2013a) Dipeptidyl peptidase IV inhibitory and antioxidative properties of milk protein-derived dipeptides and hydrolysates. Peptides
39, 157–163.
14.
Perley, MJ & Kipnis, DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest
46, 1954–1962.
15.
Nauck, M, Homberger, E, Siegel, EG
et al. (1986) Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocr Metab
63, 492–498.
16.
Kim, W & Egan, JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev
60, 470–512.
17.
Nauck, M, Stöckmann, F, Ebert, R
et al. (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia
29, 46–52.
18.
Vilsbøll, T, Krarup, T, Deacon, CF
et al. (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes
50, 609–613.
19.
Nauck, MA, Bartels, E, Orskov, C
et al. (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocr Metab
76, 912–917.
20.
Drucker, D (2003) Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Inv Drug
12, 87–100.
21.
Reimann, F, Habib, AM, Tolhurst, G
et al. (2008) Glucose sensing in L cells: a primary cell study. Cell Metab
8, 532–539.
22.
Hall, WL, Millward, DJ, Long, SJ
et al. (2003) Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr
89, 239–248.
23.
Power, O, Conway, C, McCormack, W
et al. (2011) A comparison of the insulinotropic and enterogastric response to ingestion of an equivalent quantity of maltodextran and whey protein. Proc Nutr Soc
70, E357.
24.
Hira, T, Mochida, T, Miyashita, K
et al. (2009) GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate, in rats. Am J Physiol Gastrointest Liver Physiol
297, G663–G671.
25.
Oya, M, Kitaguchi, T, Pais, R
et al. (2012) The GPRC6A receptor is involved in amino acid-induced glucagon-like peptide-1 secretion from GLUTag cells. J Biol Chem
288, 4513–4521.
26.
Reimann, F, Williams, L, Silva Xavier, G
et al. (2004) Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia
47, 1592–1601.
27.
Lindgren, O, Carr, RD, Deacon, CF
et al. (2011) Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocr Metab
96, 2519–2524.
28.
Schirra, J, Katschinski, M, Weidmann, C
et al. (1996) Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest
97, 92–103.
29.
Mentlein, R, Gallwitz, B & Schmidt, WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem
214, 829–835.
30.
Holst, JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev
87, 1409–1439.
31.
Kreymann, B, Ghatei, MA, Williams, G
et al. (1987) Glucagon-like peptide 1 7–36: a physiological incretin in man. Lancet
330, 1300–1304.
32.
Wettergren, A, Schjoldager, B, Mortensen, PE
et al. (1993) Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Digest Dis Sci
38, 665–673.
33.
Näslund, E, Bogefors, J, Skogar, S
et al. (1999) GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol Regul Integr Comp Physiol
277, R910–R916.
34.
Flint, A, Raben, A, Astrup, A
et al. (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest
101, 515–520.
35.
Rijkelijkhuizen, JM, McQuarrie, K, Girman, CJ
et al. (2010) Effects of meal size and composition on incretin, α-cell, and β-cell responses. Metabolis
59, 502–511.
36.
Kim, S-J, Nian, C & McIntosh, CHS (2007) Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. J Biol Chem
282, 8557–8567.
37.
Vilsbøll, T, Krarup, T, Madsbad, S
et al. (2003) Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept
114, 115–121.
38.
Holst, JJ & Gromada, J (2004) Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endo M
287, E199–E206.
39.
Marguet, D, Baggio, L, Kobayashi, T
et al. (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA
97, 6874–6879.
40.
Nagakura, T, Yasuda, N, Yamazaki, K
et al. (2003) Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolis
52, 81–86.
41.
Conarello, SL, Li, Z, Ronan, J
et al. (2003) Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA
100, 6825–6830.
42.
Hu, P, Yin, Q, Deckert, F
et al. (2009) Pharmacokinetics and pharmacodynamics of vildagliptin in healthy chinese volunteers. J Clin Pharmacol
49, 39–49.
43.
Ahrén, B, Landin-Olsson, M, Jansson, P-A
et al. (2004) Inhibition of dipeptidyl peptidase-IV reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocr Metab
89, 2078–2084.
44.
Yu, DMT, Yao, T-W, Chowdhury, S
et al. (2010) The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J
277, 1126–1144.
45.
Mentlein, R (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept
85, 9–24.
46.
Gorrell, MD (2005) Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci
108, 277–292.
47.
Aertgeerts, K, Ye, S, Tennant, MG
et al. (2004) Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci
13, 412–421.
48.
Rasmussen, HB, Branner, S, Wiberg, FC
et al. (2003) Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Mol Biol
10, 19–25.
49.
Kühn-Wache, K, Bär, JW, Hoffmann, T
et al. (2011) Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site. Biol Chem
392, 223–231.
50.
Lambeir, A-M, Durinx, C, Scharpé, S
et al. (2003) Dipeptidyl-Peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci
40, 209.
51.
Ahrén, B, Schweizer, A, Dejager, S
et al. (2011) Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab
13, 775–783.
52.
Rahfeld, J, Schierborn, M, Hartrodt, B
et al. (1991) Are diprotin A (Ile-Pro-Ile) and diprotin B (Val–Pro–Leu) inhibitors or substrates of dipeptidyl peptidase IV?
BBA-Protein Struct M
1076, 314–316.
53.
Hatanaka, T, Inoue, Y, Arima, J
et al. (2012) Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran. Food Chem
134, 797–802.
54.
Potashman, MH & Duggan, ME (2009) Covalent modifiers: an orthogonal approach to drug design. J Med Chem
52, 1231–1246.
55.
Hoffmann, T, Kuehn-Wache, K, Demuth, H-U
et al. (2002) inventors; OSI Pharmaceuticals, Inc., assignee. The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV. United States US 2004/0058876 A1 (Patent).
56.
Velarde-Salcedo, AJ, Barrera-Pacheco, A, Lara-González, S
et al. (2013)
In vitro inhibition of dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth (Amaranthus hypochondriacus L.) proteins. Food Chem
136, 758–764.
57.
Lorey, S, Stöckel-Maschek, A, Faust, J
et al. (2003) Different modes of dipeptidyl peptidase IV (CD26) inhibition by oligopeptides derived from the N-terminus of HIV-1 Tat indicate at least two inhibitor binding sites. Eur J Biochem
270, 2147–2156.
58.
Haque, E, Chand, R & Kapila, S (2009) Biofunctional properties of bioactive peptides of milk origin. Food Revs Int
25, 28–43.
59.
Korhonen, H (2009) Milk-derived bioactive peptides: From science to applications. J Funct Food
1, 177–187.
60.
Lacroix, IME & Li-Chan, ECY (2012) Evaluation of the potential of dietary proteins as precursors of dipeptidyl peptidase (DPP)-IV inhibitors by an in silico approach. J Funct Food
4, 403–422.
61.
Li-Chan, ECY, Hunag, S-L, Jao, C-L
et al. (2012) Peptides derived from atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors. J Agric Food Chem
60, 973–978.
62.
Huang, S-L, Jao, C-L, Ho, K-P
et al. (2012) Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates. Peptides
35, 114–121.
63.
Uenishi, H, Kabuki, T, Seto, Y
et al. (2012) Isolation and identification of casein-derived dipeptidyl-peptidase 4 (DPP-4)-inhibitory peptide LPQNIPPL from gouda-type cheese and its effect on plasma glucose in rats. Int Dairy J
22, 24–30.
64.
Uchida, M, Ohshiba, Y & Mogami, O (2011) Novel dipeptidyl peptidase-4 inhibiting peptide derived from beta-lactoglobulin. J Pharmacol Sci
117, 63–66.
65.
Tulipano, G, Sibilia, V, Caroli, AM
et al. (2011) Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors. Peptides
32, 835–838.
66.
Silveira, ST, Martínez-Maqueda, D, Recio, I
et al. (2013) Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein concentrate rich in β-lactoglobulin. Food Chem
141, 1072–1077.
67.
Tominaga, Y, Yokota, S, Tanaka, H
et al. (2012) inventors; Kaneka Corporation, assignee. Dipeptidyl peptidase-4 inhibitor. United States US 2012 0189611 (Patent).
68.
Silva-Sánchez, C, de la Rosa, APB, León-Galván, MF
et al. (2008) Bioactive peptides in amaranth (Amaranthus hypochondriacus) seed. J Agric Food Chem
56, 1233–1240.
69.
Aart, V, Catharina, M, Zeeland-Wolbers, V
et al. (2009) inventors; Newtricous B.V. , assignee. Egg protein hydrolysates. WO 2009/128713 (Patent).
70.
Foltz, M, Van Buren, L, Klaffke, W
et al. (2009) Modeling of the relationship between dipeptide structure and dipeptide stability, permeability, and ACE inhibitory activity. J Food Sci
74, H243–H251.
71.
Nongonierma, AB, Mooney, C, Shields, DC
et al. (2013b) Inhibition of dipeptidyl peptidase IV and xanthine oxidase by amino acids and dipeptides. Food Chem
141, 644–653.
72.
Fox, P, McSweeney, P (2003) Proteins. In Advanced Dairy Chemistry, 3rd ed., pp. 146–238 [Fox, P & McSweeney, P, editors]. New York: Kluwer Academic/Plenum Publishers.
73.
Boots, J (2006) inventor Campina Nederland Holding B.V., assignee. Protein hydrolysates enriched in peptides inhibiting DPP IV and thier use. WO 2006/068480 200 (Patent).
74.
Maritim, AC, Sanders, RA & Watkins, JB (2003) Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxic
17, 24–38.
75.
Abubakar, A, Saito, T, Kitazawa, H
et al. (1998) Structural analysis of new antihypertensive peptides derived from cheese whey protein by proteinase K digestion. J Diary Sci
81, 3131–3138.
76.
Durrant, J & McCammon, JA (2011) Molecular dynamics simulations and drug discovery. BMC Bio
9, 71.
77.
Pripp, A (2007) Docking and virtual screening of ACE inhibitory dipeptides. Eur Food Res Technol
225, 589–592.
78.
Norris, R, Casey, F, FitzGerald, RJ
et al. (2012) Predictive modelling of angiotensin converting enzyme inhibitory dipeptides. Food Chem
133, 1349–1354.
79.
Tanaka-Amino, K, Matsumoto, K, Hatakeyama, Y
et al. (2008) ASP4000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity. Eur J Pharmacol
590, 444–449.
80.
Mochida, T, Hira, T & Hara, H (2010) The corn protein, zein hydrolysate, administered into the ileum attenuates hyperglycemia via its dual action on glucagon-like peptide-1 secretion and dipeptidyl peptidase-IV activity in rats. Endocrinology
151, 3095–3104.
81.
Ahrén, B, Simonsson, E, Larsson, H
et al. (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care
25, 869–875.
82.
Ahrén, B, Gomis, R, Standl, E
et al. (2004) Twelve- and 52-week efficacy of the dipeptidyl peptidase IV Inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care
27, 2874–2880.
83.
Lindsay, JR, Duffy, NA, McKillop, AM
et al. (2005) Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabetic Med
22, 654–657.
84.
Nilsson, M, Holst, JJ & Bjorck, IME (2007) Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr
85, 996–1004.
85.
Power, O, Hallihan, A & Jakeman, P (2009) Human insulinotropic response to oral ingestion of native and hydrolysed whey protein. Amino Acids
37, 333–339.
86.
van Loon, L, Saris, W, Verhagen, H
et al. (2000) Plasma insulin response after ingestion of different amino acid or protein mixtures with carbohydrate. Am J Clin Nutr
72, 96–105.
87.
Nongonierma, AB & FitzGerald, RJ (2013c) Dipeptidyl peptidase IV inhibitory properties of a whey protein hydrolysate: influence of fractionation, stability to simulated gastrointestinal digestion and food-drug interaction. Int Dairy J
32, 33–39.
